Erasca to Present at Upcoming Conferences in February
Stocks in this Quantisnow insightHealth Care
Historical context for ERAS
Across the 11 sessions after earlier ERAS headlines, the stock closed higher 7 times and lower 4 times, with a median move of 4.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ERAS | SPY |
|---|---|---|---|
| Jan 27, 2026 | Mizuho resumed coverage on Erasca with a new price target | +9.3% | +0.4% |
| Jan 26, 2026 | Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | -3.5% | +0.5% |
| Jan 22, 2026 | Erasca Announces Pricing of Upsized Public Offering of Common Stock | +2.4% | +0.5% |
| Jan 21, 2026 | Erasca Announces Proposed Public Offering of $150 Million of Common Stock | +2.4% | +1.2% |
| Jan 12, 2026 | Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | -7.8% | +0.2% |
| Jan 7, 2026 | Piper Sandler initiated coverage on Erasca with a new price target | +42.4% | -0.3% |
Quantisnow market dataNASDAQ
ERAS
Erasca Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for ERAS
Full ERAS profile on Quantisnow Follow ERAS and get a push notification the moment its next story breaks.